
AACR 2023: BCG008, A Human Siglec-15 Blocking Antibody, Displays Potent Anti-Tumor Activity in Siglec-15-Humanized Mice
Conclusions BCG008 is a novel, fully human anti-SIGLEC-15 antibody generated from RenMabTM mice BCG008 has higher hSIGLEC-15 & fasSIGLEC-15 affinity and recognizes a different epitope…
Read more
AACR 2023: A Novel EGFR x MUC1 Bispecific Antibody-Drug Conjugate, BSA01, Targets MUC1 Transmembrane Cleavage Products and Improves Tumor Selectivity
Conclusions Co-expression of EGFR and MUC1 in multiple solid tumors suggests that simultaneous targeting of EGFR and MUC1 with bsADC has the potential to enhance…
Read more
AACR 2023: 1C3, A Novel Non-Blocking Anti-Human TNFR2 Antibody, Promotes Effector T Cell Responses and Demonstrates Potent Anti-Tumor Activity
Conclusions BCG003 binds to the CRD3 and CRD4 domains of TNFR2 without blocking the binding of TNFα. In vitro, BCG003 stimulates the proliferation and activation…
Read more
AACR 2023: The RenMice HiTS (Hyperimmune Target Specific) Platform Facilitates Identification of Novel Therapeutic Antibodies for Challenging Targets
Conclusions In conclusion, the RenMice™ HiTS (Hyperimmune Target Specific) Platform enables accelerated identification of fully human antibodies with increased diversity of antibody paratopes and species…
Read more
AACR 2023: Novel Humanized CD36 Mouse Model for Therapeutic Studies
Used in the poster: B-hCD36 mice Conclusions mRNA expression analysis: Mouse Cd36 mRNA was detected in lung tissue isolated from wild-type mice, while human CD36…
Read more
AACR 2023: In vivo Efficacy Evaluation of Anti-Human VEGFR2 Antibodies in Humanized B-hVEGFR2 Mice
Used in the poster: B-hVEGFR2 mice Conclusions mRNA expression analysis: Murine Vegfr2 mRNA was detected in embryonic tissue isolated from wild-type mice, while human…
Read more
AACR 2023: Humanized OX40/OX40L Mice as a Tool for Evaluating Novel Therapeutics
Used in the poster: B-hOX40/hOX40L mice Conclusions mRNA expression analysis: Mouse Ox40l mRNA was detected in dendritic cells isolated from wild-type mice, while human OX40L…
Read more
AACR 2023: Generation of Humanized TREM2 Mice for Preclinical Evaluation of Therapeutics Targeting Tumor-Associated Macrophages
Used in the poster: B-hTREM2 mice Conclusions Murine Trem2 mRNA was detected in wild-type mice, while human TREM2 mRNA was detected in homozygous B-hTREM2 mice…
Read more
AACR 2023: Development of MHC I/II Knock-Out Immunodeficient Mouse Strains for Alleviating GvHD Induced by Human PBMC Reconstitution
Used in the poster: B-NDG MHC I/II DKO mice plus Conclusions We have generated an immunodeficient model, B-NDG MHC I/II DKO mice plus, that lacks…
Read more
AACR 2023: Development of Immunodeficient Mice Expressing Human IL3, GM-CSF, CSF1 and THPO for Improved Human Myeloid and Lymphoid Cell Reconstitution
Used in the poster: B-NDG MGMT3 mice Conclusions We generated an immunodeficient (B-NDG) mouse model containing human GM-CSF, CSF1, THPO, and IL3 in place of…
Read more
AACR 2023: Identification of DM004, A First-In-Class Anti-5T4/MET Bispecific Antibody-Drug Conjugate
Conclusions DM004's parental 5T4 ADC shows excellent anti-tumor efficacy both in vitro and in vivo. The reduced binding avidity of anti-MET monovalent antibodies suggests improved…
Read more
AACR 2023: A First-In-Class Bispecific Antibody-Drug Conjugate (DM002) Targeting HER3 and the Juxtamembrane Domain of MUC1
Conclusions HER3 and MUC1 are co-expressed in a variety of solid tumors, especially those with the highest mortality. DM002 is a novel fully human bispecific…
Read more